jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Abdomen mass biopsy - Medium 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Diagnostic procedure used to evaluate a suspicious growth or lesion in the abdominal cavity

₹349₹1,000

65% OFF

Abdomen Mass Biopsy - Medium 1-3 cm: Comprehensive Medical Test Guide

  • Why is it done?
    • Test Purpose: Obtain tissue samples from abdominal masses measuring 1-3 cm to determine their histological nature, distinguish between benign and malignant lesions, identify specific disease processes, and guide treatment decisions.
    • Primary Indications: Evaluation of incidental abdominal masses discovered on imaging; suspected malignancy; characterization of cystic or solid lesions; confirmation of metastatic disease; assessment of lymph node enlargement; evaluation of pancreatic, liver, kidney, or adrenal masses; suspected inflammatory or infectious processes.
    • Timing and Circumstances: Performed when imaging (CT, MRI, ultrasound) identifies a mass requiring tissue diagnosis; typically scheduled within 1-4 weeks of imaging discovery; urgent if malignancy is highly suspected; performed as outpatient procedure under imaging guidance.
  • Normal Range
    • Normal Finding: Benign tissue without evidence of malignancy, inflammation, or infection. Results show normal or reactive cells specific to the organ of origin.
    • Interpretation Categories: Benign (negative) - No malignant cells identified; Malignant (positive) - Cancerous cells present with specific classification; Atypical/Suspicious - Uncertain findings requiring follow-up; Non-diagnostic - Insufficient tissue for definitive diagnosis; Inflammatory/Infectious - Evidence of specific disease process.
    • Units of Measurement: Histological classification based on cell morphology, staining patterns, immunohistochemical markers, and molecular testing when applicable.
  • Interpretation
    • Benign Results: Indicates no cancer present; may include lipomas, cysts, fibromas, or inflammatory lesions; often requires only surveillance imaging or clinical follow-up depending on specific diagnosis.
    • Malignant Results: Confirms cancer diagnosis; identifies specific cancer type (adenocarcinoma, lymphoma, sarcoma, etc.); guides chemotherapy, radiation, or surgical planning; determines prognosis and staging; establishes molecular markers for targeted therapy.
    • Atypical/Suspicious Results: Cells show concerning features but lack definitive malignant characteristics; may represent dysplasia or early neoplastic changes; typically requires repeat biopsy, increased surveillance, or alternative imaging within 3-6 months.
    • Non-diagnostic/Inconclusive: Insufficient tissue obtained; may be due to small mass size or technical factors; requires repeat sampling or alternative diagnostic approach such as larger core biopsy or surgical intervention.
    • Inflammatory/Infectious: Evidence of infection (abscess, tuberculosis) or inflammatory disease (sarcoidosis, Crohn's disease); may include culture, special stains, or molecular testing for infectious organisms.
    • Factors Affecting Interpretation: Sample adequacy (cellularity and representativeness); needle type and number of passes obtained; prior chemotherapy or radiation effects; presence of necrosis or hemorrhage within mass; contamination or technical processing issues.
  • Associated Organs
    • Primary Organ Systems: Liver, pancreas, kidney, adrenal glands, spleen, lymph nodes, gastrointestinal tract, peritoneum, mesentery, and retroperitoneal structures.
    • Common Associated Conditions: Hepatocellular carcinoma, pancreatic adenocarcinoma, renal cell carcinoma, lymphoma, adrenocortical tumors, gastrointestinal stromal tumors (GIST), sarcomas, metastatic disease, tuberculosis, sarcoidosis, abscesses.
    • Diseases Diagnosed or Monitored: Primary malignancies, metastatic cancer, lymphoproliferative disorders, infection, autoimmune conditions, and metabolic diseases affecting abdominal organs.
    • Potential Complications: Pneumothorax (if lung tissue involved), hemorrhage, organ perforation, infection, pancreatitis (pancreatic biopsy), bile peritonitis (liver biopsy), tumor seeding (rare), and pain at biopsy site.
  • Follow-up Tests
    • If Malignancy Confirmed: CT or MRI staging studies; molecular and genetic testing (gene mutations, expression profiling); tumor markers (CEA, PSA, alpha-fetoprotein); immunohistochemistry for prognostic markers; multidisciplinary tumor board review.
    • If Benign Results: Follow-up imaging at 3-6 months if recommended; clinical examination; baseline imaging for comparison; possible repeat ultrasound or CT depending on lesion characteristics.
    • If Atypical/Inconclusive: Repeat biopsy within 3-6 months with increased sampling; advanced imaging (MRI, PET-CT); consultation with specialized radiologists or pathologists; possible surgical consultation.
    • If Infection Identified: Culture and sensitivity testing; special stains (acid-fast bacilli for TB); molecular PCR testing; imaging to assess extent; antimicrobial therapy initiation; clinical response monitoring.
    • Complementary Tests: PET-CT for metastatic evaluation, bone scan for bone involvement, laboratory biomarkers, flow cytometry (for lymphomas), endoscopy/colonoscopy (if GI involvement), liver function tests, renal function tests.
  • Fasting Required?
    • Fasting Requirement: YES - Fasting is typically required for 4-6 hours before the procedure.
    • Fasting Duration and Instructions: NPO (nothing by mouth) for 4-6 hours before biopsy; clear liquids may be allowed up to 2 hours before procedure depending on facility protocol; arrive 15-30 minutes early for check-in and paperwork.
    • Medications to Avoid: Anticoagulants (warfarin, apixaban, rivaroxaban) - typically held 3-5 days before; antiplatelet agents (aspirin, clopidogrel) - usually held 3-7 days; NSAIDs - discontinued 5-7 days prior; certain herbal supplements (ginger, ginseng, garlic); check with physician regarding specific medications.
    • Additional Patient Preparation: Sign informed consent forms; disclose bleeding disorders or anticoagulation therapy; report allergies (especially contrast media or local anesthetics); wear comfortable, loose-fitting clothes; arrange transportation (sedation may be used); baseline coagulation studies (PT/INR, PTT, platelet count) may be ordered; bowel preparation if imaging requires it.

How our test process works!

customers
customers